Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sung Bae Lee

Vascular Neurology Gainesville, GA Medical Doctor

NPI 1740260231 CMS profile 351130

1315 Jesse Jewell Pkwy Ne Ste 300, Gainesville, GA 30501

Open in the dashboard

General payments

$1,206

27 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,462 paid to institutions, not to them · program years 2022–2024

Through program year 2025, Sung Bae Lee of Gainesville, GA is reported in the CMS Open Payments database as having received $1,206 across 27 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,462 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 54th percentile of Vascular Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $263 2
2024 General $100 2
2023 General $239 7
2022 General $329 6
2021 General $92 5
2020 General $49 2
2019 General $133 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sung Bae Lee
  • Vascular Neurology median
  • Middle half of Vascular Neurology
  • National median

In program year 2025, general payments to Sung Bae Lee were reported at $263. Among 416 Vascular Neurology profiles paid that year, the median was $360 and the middle half received between $91 and $1,472.

Show as a table
Year Sung Bae Lee Vascular Neurology median Middle half National median
2019 $133 $263 $102–$1,640 $163
2020 $49 $153 $45–$1,000 $114
2021 $92 $261 $100–$1,355 $132
2022 $329 $242 $87–$1,273 $149
2023 $239 $322 $97–$1,266 $160
2024 $100 $247 $70–$1,053 $164
2025 $263 $360 $91–$1,472 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Microtransponder, Inc. $218 1 payment
  2. Medtronic, Inc. $174 3 payments
  3. MicroVention, Inc. $166 2 payments
  4. Novo Nordisk Inc $104 1 payment
  5. Medtronic Vascular, Inc. $89 1 payment
  6. Silk Road Medical, Inc. $81 1 payment
  7. Medtronic USA, Inc. $49 2 payments
  8. InspireMD Ltd $45 1 payment
  9. UCB, Inc. $42 2 payments
  10. Siemens Medical Solutions USA, Inc. $36 2 payments
  11. Other $204 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,206 27 payments
Products named General payments · program years 2019–2025
  1. SOLITAIRE X $154 2 payments
  2. WEB ANEURYSM EMBOLIZATION SYSTEM $146 1 payment
  3. STENT $146 1 payment
  4. Concerto $89 1 payment
  5. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $81 1 payment
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $81 1 payment
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $81 1 payment
  8. ENROUTE Transcarotid Stent $81 1 payment
  9. CGuard Prime Carotid Stent System $45 1 payment
  10. Briviact $42 2 payments
  11. Other $399 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

28

Median for Neuropsychiatry: 88

Drug cost

$6,157

Median for Neuropsychiatry: $2,689

Branded share of claims

60.7%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 17 $5,975
Levetiracetam Generic 11 $182

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$60,746

Medicare's payments for the services billed

Medicare patients

125

Average age 75

Services billed

392

82 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Chronic kidney disease 32%
Ischemic heart disease 30%
Depression 29%
Atrial fibrillation 28%
Diabetes 24%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

27 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record